Search - tctmd.com

Displaying 641 - 653 of 653

Sort: Relevancy | Date

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

July 27, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

June 09, 2015

News Daily News

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

June 09, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Industry News

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

June 02, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

Todd Neale

January 28, 2015

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

Todd Neale

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

CME

The Role of Atrial Shunts in the Treatment of HFpEF

CME

State of the Art: Creating Left-to-Right Shunts as a Treatment for Chronic Heart Failure

Evaluating the Heart Failure Patient with MR: Integrating Train Data Into Clinical Practice

CME

Advertisement

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

The Role of Atrial Shunts in the Treatment of HFpEF

State of the Art: Creating Left-to-Right Shunts as a Treatment for Chronic Heart Failure

Evaluating the Heart Failure Patient with MR: Integrating Data Into Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content